These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18260897)

  • 21. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
    Stone GW; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri E; Gurbel PA; Xu K; Parise H; Kirtane AJ; Brodie BR; Mehran R; Stuckey TD;
    Lancet; 2013 Aug; 382(9892):614-23. PubMed ID: 23890998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and very long- term outcomes of stent thrombosis after bare-metal or drug-eluting stent implantation: a retrospective analysis.
    Pullara A; Longo G; Gonella A; D'Ascenzo F; Biondi Zoccai G; Moretti C; Sciuto F; Omedè PL; Bollati M; Gaita F; Sheiban I
    Minerva Cardioangiol; 2013 Feb; 61(1):1-9. PubMed ID: 23381375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
    Byrne RA; Schulz S; Mehilli J; Iijima R; Massberg S; Neumann FJ; ten Berg JM; Schömig A; Kastrati A;
    Am Heart J; 2009 Apr; 157(4):620-4.e2. PubMed ID: 19332187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
    Maeng M; Jensen LO; Kaltoft A; Hansen HH; Bøttcher M; Lassen JF; Thayssen P; Krusell LR; Rasmussen K; Pedersen L; Sørensen HT; Johnsen SP; Thuesen L
    Am J Cardiol; 2008 Jul; 102(2):165-72. PubMed ID: 18602515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
    Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
    EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients: three-year follow-up results.
    Chen JL; Gao LJ; Yang YJ; Li JJ; Qiao SB; Xu B; Huang JH; Yao M; Qin XW; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Gao RL
    Chin Med J (Engl); 2010 Apr; 123(7):778-81. PubMed ID: 20497663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents.
    Zimarino M; Renda G; De Caterina R
    Drugs; 2005; 65(6):725-32. PubMed ID: 15819586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
    Camenzind E; Wijns W; Mauri L; Boersma E; Parikh K; Kurowski V; Gao R; Bode C; Greenwood JP; Gershlick A; O'Neill W; Serruys PW; Jorissen B; Steg PG;
    Am Heart J; 2009 Dec; 158(6):902-909.e5. PubMed ID: 19958855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Very" very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation.
    Kaliyadan A; Siu H; Fischman DL; Ruggiero NJ; Jasti B; Walinsky P; Ogilby JD; Savage MP
    J Invasive Cardiol; 2014 Sep; 26(9):413-6. PubMed ID: 25198482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
    Dangas GD; Caixeta A; Mehran R; Parise H; Lansky AJ; Cristea E; Brodie BR; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Möeckel M; Stone GW;
    Circulation; 2011 Apr; 123(16):1745-56. PubMed ID: 21482968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
    Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
    Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late and very late stent thrombosis after polymer-based sirolimus- or paclitaxel-eluting stent implantation in real-world clinical practice.
    Shen WF
    Chin Med J (Engl); 2010 Apr; 123(7):773-5. PubMed ID: 20497661
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
    Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents.
    Leibundgut G; Nietlispach F; Pittl U; Brunner-La Rocca H; Kaiser CA; Pfisterer ME
    Am Heart J; 2009 Aug; 158(2):271-6. PubMed ID: 19619705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Stents in interventional cardiology].
    Grinius V; Navickas R; Unikas R
    Medicina (Kaunas); 2007; 43(3):183-9. PubMed ID: 17413246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late and very late stent thrombosis in patients with second-generation drug-eluting stents.
    Huang KN; Grandi SM; Filion KB; Eisenberg MJ
    Can J Cardiol; 2013 Nov; 29(11):1488-94. PubMed ID: 23830291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.